ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Immunological drivers of oxidative stress in glaucoma: implications for antioxidant therapy.
Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Glaucoma is a progressive neurodegenerative disorder characterized by RGC loss and irreversible visual impairment, representing the second leading cause of global blindness. Immune-inflammatory responses and oxidative stress are core pathological drivers of glaucomatous optic nerve degeneration, forming a vicious cycle via the TLR4/NF-κB/NLRP3 inflammasome axis, complement overactivation, and dysregulation of the endogenous antioxidant system. These processes trigger sustained neuroinflammation, mitochondrial dysfunction, and RGC apoptosis. Antioxidant therapies targeting the immune-oxidative stress axis have emerged as promising neuroprotective strategies, including classic antioxidants, Nrf2 activators (e.g., NOB), nanocarrier-mediated targeted delivery systems, and PBM. This mini-review summarizes key molecular mechanisms linking immune activation and oxidative damage in glaucoma, reviews recent advances in the development of antioxidant therapeutics, and discusses current challenges and future directions for clinical translation.
Indexed as
Identifiers
42570082What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.